Finasteride (Synonyms: MK-906) |
| رقم الكتالوجGC16248 |
فيناسترايد (MK-906) هو مثبط اختزال 5α قوي وتنافسي ، مع IC 50 من 4.2 نانومتر للنوع II 5α-reductaseيمتلك فيناسترايد تقاربًا أكبر بمقدار 100 ضعف تقريبًا للنوع الثاني من إنزيم اختزال 5α مقارنة بالنوع الأول من الإنزيميمكن استخدام الفيناسترايد في البحث عن تضخم البروستاتا الحميد (BPH) والثعلبة الأندروجينية
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 98319-26-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM). Target: 5-alpha ReductaseApproved: 1992Finasteride, a synthetic 4-azasteroid antiandrogen compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Finasteride is used in the treatment of prostate cancer, benign prostatic hyperplasia, and androgenetic alopecia (male pattern baldness). In benign prostatic hyperplasia, finasteride inhibits 5alpha-reductase activity in epithelium for Ki of 10 nM, significantly lower than in stroma (Ki = 33nM) [1].
References:
[1]. Weisser, H. and M. Krieg, In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol, 1998. 67(1): p. 49-55.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *